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RESUMO 
Avaliação do Stent Coronário Eluidor de  
Everolimus XIENCETM V na População Feminina 
Latino-Americana do Estudo de Braço Único  
SPIRIT Women: Acompanhamento Clínico de Um Ano
Introdução: Os estudos com stents farmacológicos têm avaliado 
predominantemente populações masculinas de descendência 
europeia. O estudo de braço único SPIRIT Women avalia o 
stent eluidor de everolimus XIENCETM V em lesões de novo 
complexas em uma população feminina do mundo real, 
incluindo pacientes latino-americanas. Esta análise permite 
compreender como essa população responde ao implante de 
stent, comparativamente a pacientes não-latino-americanas. 
Métodos: Das 1.572 pacientes matriculadas em 73 locais fora 
dos Estados Unidos, 138 (9%) foram recrutadas na Argentina, 
no Brasil e na Venezuela. Resultados: As lesões-alvo tinham 
diâmetro de referência do vaso entre 2,25 mm e 4 mm e 
extensão da lesão < 28 mm. As características basais foram 
semelhantes entre os grupos, com exceção de maior prevalên cia 
de hipertensão arterial, infarto do miocárdio (IM) de parede 
anterior e história familiar de doença arterial coronária na 
coorte latino-americana. As lesões tendiam a ser mais com-
plexas em mulheres latino-americanas, com menor diâmetro 
de referência do vaso-alvo, maior extensão da lesão, maior 
excentricidade e angulação e mais lesões tipo B2/C. Os eventos 
ABSTRACT
Background: Drug-eluting stent trials have predominantly exa-
mined male populations of European descent. SPIRIT Women 
single-arm study evaluates the XIENCETM V everolimus-eluting 
stent in complex de novo lesions in a real world female po -
pulation, including Latin American patients. This analysis pro-
vides an insight into how this population responds to stenting 
when compared to non-Latin American patients. Methods: Of 
the 1,572 patients enrolled from 73 non-US sites, 138 (9%) 
were recruited from Argentina, Brazil and Venezuela. Results: 
Target lesions had reference vessel diameter ranging between 
2.25 mm and 4 mm and lesion length < 28 mm. Baseline 
characteristics were similar between the groups, with exception 
to a higher prevalence of hypertension, anterior myocardial 
infarction (MI) and family history of coronary artery disease 
in the Latin American cohort. Lesions tended to be more 
complex in Latin American women with a smaller reference 
vessel diameter, longer lesion length, increased eccentricity 
and angulation, and more type B2/C lesions. Events were 
adjudicated according to the guidelines of the Academic 
Research Consortium. At 1 year, the composite endpoint 
of death, MI and target vessel revascularization (TVR) was 
12.1% in the non-Latin American population and 10.1% in 
the Latin American population (P = 0.58). Conclusions: At 1 
year, the low rates of adverse cardiac events, including stent 
thrombosis, target lesion failure, cardiac death, MI and TVR 
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Environmental and genetic risk factors, such as abdo-minal obesity, diabetes, dyslipidemia, smoking, and hypertension have been identified as predisposing 
factors for the female Latin American population to a 
significantly increased risk of cardiovascular events. 
Drug-eluting stents are now widely accepted as safe 
and effective therapies for patients with coronary artery 
disease. Drug-eluting stents inhibit neointimal prolife-
ration by locally delivering an anti-proliferative drug, 
reducing the restenosis rate and the need for repeat 
revascularization procedures.1 
The XIENCETM V (everolimus-eluting stent system 
Abbott Vascular, Santa Clara, USA) was extensively 
evaluated in the SPIRIT clinical trials. SPIRIT FIRST2 
and SPIRIT II3, where XIENCETM V was evaluated, res-
pectively, against the bare metal MULTI-LINK VISION™ 
RX stent (Guidant Vascular Intervention, Santa Clara, 
USA) and the paclitaxel-eluting stent TAXUS ™ (Boston 
Scientific, Natick, USA), demonstrated superiority when 
compared to the latter in terms of in-stent late loss at 
6 months. Subsequently, this improvement in clinical 
outcomes was demonstrated in up to 5 years of fol low-
up in SPIRIT FIRST.4 SPIRIT III demonstrated superiority 
to XIENCE™ V when compared to TAXUS ™ in terms 
of in-segment late loss at 8 months and non-inferiority 
for the secondary endpoint of target vessel failure at 
9 months.5 In addition, patients treated with the eve-
rolimus eluting stent in this study had a significantly 
improved event-free survival at 2 years when compared 
to patients receiving the TAXUS ™ stent.6
The aforementioned SPIRIT trials were primarily 
carried out in male populations of European descent 
with a relatively low-risk profile and simple lesions. 
When compared to the rest of the world, the Latin 
America population has shown a higher prevalence of 
diabetes and hypertension7 and a high proportion of 
smokers, especially in big cities.8
The present manuscript reports the clinical follow-up 
data at 1 year in the Latin American population com-
pared to the non-Latin American (non-Latin American) 
population of the SPIRIT Women Single Arm Study. 
This study evaluated the performance of XIENCE™ V 
in complex de novo lesions in a real world female 
population (n = 1,572). A significant proportion of 
the study population (138 patients; 9%) was recruited 
from Latin American sites in Argentina, Brazil and 
Venezuela, thereby providing insight into how this 
population responds to the implant of everolimus elu-
ting stents when compared to the non-Latin American 
patient population. 
METHODS
Study design and patient selection
SPIRIT Women is a prospective, single arm, mul-
ti-center study aimed at evaluating the performance of 
XIENCE™ V in the real world, according to its instruc-
tions for use, in the treatment of female patients with 
de novo coronary artery lesions. The study protocol 
was approved by the medical ethics committee of each 
participating institution and all patients gave written 
informed consent.
Between July 2007 and March 2009, 1,572 patients 
were enrolled at 73 clinical sites outside the United 
States, of which 9% (n = 138) were recruited from 
sites in Argentina (36), Brazil (82) and Venezuela (20). 
Patients (aged > 18 years) recruited from the gene-
ral interventional cardiology population who had been 
admitted for a PCI procedure, were recruited for the 
study. Inclusion criteria included patients with evidence 
of myocardial ischemia, stable or unstable angina, silent 
ischemia or a positive functional study, or a reversible 
change in the ECG consistent with ischemia. Patients 
were required to be suitable candidates for myocardial 
revascularization and had to agree to undergo clinical 
follow-up as required per protocol. Patients of child 
bearing potential should have a negative pregnancy 
test within 7 days before treatment. In addition, coro-
in Latin American women were comparable to those of the 
non-Latin American women, despite the higher complexity of 
lesions. These results demonstrate the safety and efficacy of 
the XIENCETM V stent in this small cohort of Latin American 
patients, in line with what is observed in larger and more 
varied populations.
DESCRIPTORS: Coronary artery disease. Drug-eluting stents. 
Women. Latin America. 
foram adjudicados de acordo com as definições do Academic 
Research Consortium. Em um ano, o desfecho combinado de 
morte por todas as causas, IM e revascularização do vaso-alvo 
(RVA) foi de 12,1% na população não-latino-americana e de 
10,1% na população latino-americana (P = 0,58). Conclusões: 
Em um ano, os baixos índices de eventos cardíacos adver-
sos, incluindo trombose do stent, falha da lesão-alvo, morte 
cardíaca, IM e RVA nas mulheres latino-americanas foram 
comparáveis aos das mulheres não-latino-americanas, apesar da 
maior complexidade das lesões. Esses resultados demonstram 
a segurança e a eficácia do stent XIENCETM V nessa pequena 
coorte de pacientes latino-americanas, à semelhança do que 
é observado com populações maiores e mais variadas. 
DESCRITORES: Doença da artéria coronariana. Stents farma-
cológicos. Mulheres. América Latina. 
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nary anatomy should allow an optimal treatment with 
a maximum of 4 stents planned for de novo target 
lesions with target vessel reference diameter between 
2.25 mm and 4.0 mm, target lesion length ≤ 28 mm 
by visual estimation. Patients were excluded if they had 
participated in another device or drug study or had 
completed the follow-up phase of another study within 
30 days prior to enrolment or if they had undergone 
previous stenting, be it a bare metal or drug-eluting 
stent in the target vessel. 
 The XIENCE™ V everolimus-eluting stent
A detailed description of the device has been pu -
blished elsewhere.9 In brief, XIENCE™ V everolimus-
elu ting stent system includes MULTI LINK VISION™ 
metal platform on a delivery system with drug eluting 
coating. The drug eluting coating is composed of 
fluorinated acrylic polymers and the anti-proliferative 
drug everolimus (Certican®, Novartis Pharmaceuticals 
Corporation, Basel, Switzerland). Stents are available 
in diameters of 2.25, 2.5, 2.75, 3.0, 3.5 and 4.0 mm 
and lengths of 8, 12, 15, 18, 23 and 28 mm. 
Study procedure 
Following confirmation of the angiographic inclusion 
criteria and before implantation of the first stent, pa-
tients were entered via an interactive voice response 
system (ICON Clinical Research, Eastleigh, UK). All 
registered patients were considered enrolled in the 
study and were to remain in the study until completion 
of the required follow-up period. Periprocedural drug 
therapy was administered according to standard hos-
pital practice. Unfractionated heparin or bivalirudin 
was used for procedural anticoagulation. The use of 
glycoprotein IIb/IIIa inhibitors was left to the discretion 
of the operator. All patients enrolled in the study were 
to receive a loading dose ≥ 300 mg of clopidogrel. 
After the procedure the protocol recommended that 
patients receive a daily dose of 75 mg of clopidogrel 
for a minimum of 6 months and ≥ 75 mg of aspirin 
daily indefinitely. 
Follow-up 
Clinical follow-up was scheduled at 30 days, 1 
year and 2 years after the procedure and included 
assessment of angina, adverse event data collection, 
details of subsequent coronary intervention, protocol 
required medications and use and changes of conco-
mitant medications. 
Study endpoints 
The primary endpoint was the composite inciden-
ce of all death, myocardial infarction (MI) and target 
vessel revascularization (TVR) at 1 year. Secondary 
endpoints included but were not limited to acute 
suc cess (clinical device and procedure) and stent 
throm bosis rates.
Source document verification 
Source document verification was routinely per-
formed in 20% of random cases and 100% of all re-
ported adverse events during the study, resulting in an 
overall rate of 30%. For sites with low rates of adverse 
event reporting, additional monitoring visits and source 
document verification were performed. All endpoint 
related events were adjudicated by an independent 
Clinical Events Committee (CEC) that had access to 
source documentation.
Definitions 
All study endpoint events were adjudicated by an 
independent CEC according to the Academic Research 
Consortium (ARC) definitions.10 All adverse events were 
reported bimonthly to an independent Data and Safety 
Monitoring Board (DSMB) which reviewed data to iden-
tify safety issues related to the conduct of the study.
– Death: All deaths were considered cardiac unless 
an unequivocal non-cardiac cause could be established. 
Specifically, any unexpected death, even in patients 
with coexisting potentially fatal non-cardiac disease 
(e.g. cancer, infection), were classified as cardiac.
– Cardiac death: Any death due to immediate car-
diac cause (e.g. MI, low cardiac output syndrome, fatal 
arrhythmia). Unwitnessed death and death of unknown 
cause were classified as cardiac death. This included 
all procedure-related deaths including those related to 
concomitant treatment.
– Myocardial infarction: MI classification and criteria for 
diagnosis were defined according to the ARC as follows: 
for non-procedural/spontaneous MI, troponin or CK-MB 
levels had to be > 2 times the upper normal range; for 
peri-percutaneous coronary intervention, troponin or 
CK-MB levels had to be ≥ 3 times the upper normal 
range; for peri-myocardial revascularization, troponin or 
CK-MB levels had to be ≥ 5 times the upper normal 
range. The peri-procedural period included the first 
48h and 72h after percutaneous coronary intervention 
and myocardial revascularization, respectively. All late 
events that were not associated with a revascularization 
procedure were considered spontaneous. One blood 
sample was taken from each patient within the post-
-procedure hospitalization period for the analysis of 
CKMB or troponin levels.
– Target lesion revascularization: TLR is defined as 
any repeat percutaneous intervention or bypass surgery 
to treat any segment of the target vessel. The target 
lesion is defined as a segment 5 mm proximal and 5 mm 
distal to the stent.
– Target vessel revascularization: TVR is defined as 
any repeat percutaneous intervention or surgical bypass 
of any segment of the target vessel. It is defined as the 
major coronary vessel, which includes the target lesion 
and its proximal and distal branches. 
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– Target lesion failure: TLF is defined as cardiac death, 
target vessel MI, or ischemia-driven TLR (percutaneous 
coronary intervention or myocardial revascularization).
– Stent thrombosis: Characterized as acute (< 1 day), 
subacute (1-30 days) and late (> 30 days) and defined 
according to the ARC guidelines as definitive (acute 
coronary syndrome with angiographic or pathologic 
confirmation of stent thrombosis); probable (unexplained 
death ≤ 30 days or target vessel-MI without angiogra-
phic confirmation); and possible (unexplained death 
> 30 days after stent placement).
– Clinical device success: Successful delivery and 
deployment of the study stent (in case of stent overlap-
ping, a successful delivery and deployment of the first 
and second stents) at target lesion and successful with-
drawal of the stent delivery system with final residual 
stenosis < 50% of the target lesion by quantitative 
coronary angiography (QCA) (or by visual estimation 
if QCA unavailable), without using a device outside 
the assigned treatment strategy. Bailout patients were 
included as clinical device success only if the above 
criteria were met.
– Clinical procedure success: Successful delivery 
and deployment of the study stent or stents at the in-
tended target lesion and successful withdrawal of the 
stent delivery system with final residual stenosis < 50% 
of the target lesion by QCA (or by visual estimation if 
QCA unavailable) and/or using any adjunctive device 
without the occurrence of cardiac death, MI not clearly 
attributed to a non-target vessel and/or TLR during hos -
pital stay within a maximum of seven days of the index 
procedure. In multiple lesions setting each lesion must 
have met clinical procedure success criteria.
Statistical analysis 
All analyses were performed based on the intent 
to treat population. The study sample size was based 
on the primary endpoint of the composite rate of all 
death, MI and TVR at 1 year. A sample size of 1,550 
patients would produce a narrow two-sided 95% con-
fidence interval for the clinical endpoints estimates. 
The ½ width of the 2-sided confidence interval for 
the primary endpoint would range between 1.5% and 
1.7%, assuming the true rate between 10% and 14%. 
Continuous variables are summarized as mean and 
standard deviation and compared with a t-test. Binary 
variables are presented as percentages and compared 
with the Fisher’s exact test. P-values are not based 
on a formal hypothesis testing and are displayed for 
descriptive purpose only.
RESULTS
Nine percent (138/1572) of the SPIRIT Women po -
pulation was recruited from sites within Latin America, 
including 59% (82/138) from sites in Brazil; 26% (36/138) 
from sites in Argentina and 14% (20/138) from sites in 
Venezuela. At 1 year, clinical follow-up was obtained 
in 100% of the Latin American patients and in 98.0% 
of the patients at non-Latin American sites.
There was no significant difference in the overall 
mean age between patients recruited from Latin Ame-
rican sites when compared to those from non-Latin 
American sites (Table 1). However, there was a trend 
for the Latin American patients to be younger with 
46.4% of patients with ages ranging between 18-65 
years vs. 38.5% of patients from non-Latin American 
sites (P = 0.08). When compared to non-Latin American 
patients, Latin American patients had a higher preva-
lence of hypertension requiring medication (85% vs. 
77%; P = 0.03), prior myocardial infarction (33% vs. 
25%; P = 0.03), and family history of coronary artery 
disease (51% vs. 35%; P < 0.001). Latin American 
patients had an increased body mass index (28.5kg/m2 
vs. 27.5 kg/m²; P = 0.03), which was primarily driven 
by a lower mean height as there was no difference 
in mean weight between the two patient populations. 
Resting diastolic blood pressure was also higher in the 
Latin American population (77 mm Hg vs. 74 mm Hg; 
P = 0.004), whereas resting systolic blood pressure 
was higher in the non-Latin American population 
(136 mm Hg vs. 132 mm Hg p=0.03). There was a 
trend to more frequent diabetes in the Latin American 
population when compared with the non-Latin Ameri-
can population (40.9% vs. 33.5%; P = 0.09), and the 
non-Latin American population was more likely to be 
treated with oral hypoglycemic medication (25% vs. 
19%; P = 0.09) or exercise and diet (6.6% vs. 2.9%; 
P = 0.04). There was a significantly higher number of 
non-Latin American patients who were diagnosed with 
renal failure (11% vs. 3%, respectively; P = 0.002).
The administration of GPIIb/IIIa medication prior to 
the index procedure was much less frequent in the Latin 
American population (2.9% in Latin American patients 
vs 14.3% in non-Latin American patients; P < 0.0001). 
A total of 2,246 lesions were treated (Table 2). The re 
was no difference in the number of target lesions between 
the two populations. The reference vessel diameter was 
significantly smaller in the Latin American population 
(2.75 mm vs. 2.90 mm; P < 0.001), however the ste-
nosis diameter was greater in the non-Latin American 
population (83.2% vs. 80.6%; P < 0.001). Type B2/C 
lesions (American College of Cardiology/American Heart 
Association) was higher in Latin American patients 
when compared to non-Latin American patients (82.2% 
vs. 70.8%; P = 0.001). The prevalence of bifurcation 
lesions was comparable between the two populations; 
however eccentricity and angulation were more preva-
lent in the Latin American population. Target lesions 
were on average 2 mm longer in the Latin American 
population (17.0 mm vs 15.1 mm) who had lesions 
> 20 mm when compared to 27.8% in the non-Latin 
American population. 
Grinfeld et al.
SPIRIT Women Latin American Population
Rev Bras Cardiol Invasiva. 
2012;20(3)
5
As shown in Table 3 at 1-year the primary compo-
site endpoint of all death, MI and TVR was comparable 
between the Latin American and non-Latin American 
populations. In addition, target vessel failure (cardiac 
death, TV-MI and TLR) was not significantly different 
between the two populations within 1 year of follow-up. 
No difference was observed in non-hierarchical event 
rates within 1 year of follow-up between the two po-
pulations. Stent thrombosis rates (definite and probable) 
were low in the two study populations, with the 1-year 
cumulative stent thrombosis rate of 0 in Latin American 
patients and 0.65% in non-Latin American patients.
DISCUSSION 
The importance of observational research, particu-
larly post-approval registries with drug eluting stents, 
has increased in recent years as they provide real world 
safety data in larger and more representative patient 
populations than controlled clinical trials. The SPIRIT 
TABLE 1 
Baseline patient characteristics
 
Latin American
(n = 138)
Non-Latin American
(n = 1,434) P Value
Age, years 65 ± 10 67 ± 10.8 0.11
Current smoker, % 15.9 14.3 0.61
Hypertension*, % 85.4 77.1 0.03
Hypercholesterolemia*, % 64.6 63.5 0.85
Diabetes, % 40.9 33.5 0.09
Insulin-dependent diabetes, % 8.8 10.9 0.56
Family history of CAD, % 51.1 34.7 < 0.001
Prior cardiac intervention, % 15.2 17.4 0.56
Prior MI, % 33.3 24.8 0.03
Patients with > 1 target lesion, % 34.8 31.4 0.44
Number of target lesions 1.4 ± 0.7 1.4 ± 0.7 0.92
* Requiring medication.
CAD = coronary artery disease; MI = myocardial infarction; n= number of patients.
TABLE 2 
Baseline lesion characteristics*
 
Latin American
(n = 198)
Non-Latin American
(n = 2,048) P Value
Type B2/C lesion, % 82.2 70.8 < 0.001
Type C, D, F, G bifurcation†, % 100 84.8 0.60
Left main, % 0.5 1.1 0.71
Longer lesions ≥ 20 mm, % 36.9 27.8 0.008
Calcification – moderate or severe, (% 24.7 30.4 0.10
Thrombus, % 4 6.3 0.27
Eccentric lesion, % 79.8 41 < 0.001
Lesion angulation > 45°, % 31.3 21.7 < 0.001
Stenosis diameter, % 80.6 ± 11.7 83.2 ± 11.3 < 0.001
Reference vessel diameter, mm 2.75 ± 0.37 2.90 ± 0.43 < 0.001
Lesion length, mm 17 ± 6.6 15.1 ± 6.4 < 0.001
* Visual assessment by the investigator.
† Medina classification 1,1,0; 1,1,1; 1,0,1; 0,1,1.
n = number of patients.
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Women Single Arm study, as a multinational trial, 
provides not only a large database with a sufficient 
number of outcomes to be analyzed, but also allows 
for the comparison of geographical variations among 
female patients with complex de-novo lesions treated 
with the XIENCE™ V stent.
Latin America is the fourth largest geographic area 
in the world, with an estimated population close to 380 
million inhabitants distributed in its 12 countries. Latin 
American citizens represent a conglomerate of different 
cultures and the socioeconomic status of the population 
is quite heterogeneous. The use of drug eluting stents 
has increased significantly in this region, from 2% in 
2002 to more than 25% in 2007.11 Different international 
clinical trials and observational registries, primarily in 
patients with heart failure and acute coronary syndro-
mes, have documented that geographic location may 
affect baseline characteristics, process of care as well 
as patients´ outcomes.12-16 However, little information 
is available in the context of drug-eluting stents. The 
E-Five Registry, a large prospective, nonrandomized, 
mul ticenter, international registry, assessed the safety and 
effectiveness of the Endeavor™ zotarolimus-eluting stent 
(Medtronic, Minneapolis, USA) in real-world patients 
with symptomatic coronary artery disease undergoing 
per cutaneous coronary intervention. Latin American 
pa tients, when compared to Europeans had a higher 
rate of hypertension and prior myocardial infarction, 
a finding that coincides with the data gathered in this 
study.17 We also found a higher prevalence of family 
history of cardiovascular disease and body mass index, 
and a trend toward higher diabetes (40.9% vs. 33.5%). 
Lesion characteristics were also different; being more 
complex and eccentric, with longer lesion length and 
smaller diameter vessels among Latin American females 
when compared to non-Latin American females. However, 
the rate of use of GPIIb/IIIa was significantly lower in 
Latin America, a finding that is frequently seen in this 
region, most likely due to economical factors.
Despite the above-mentioned differences, clinical 
outcomes were comparable between Latin American 
and non-Latin American patients, as evidenced also 
by the E-five registry. Prior reports had shown that the 
inclusion of Latin American patients was an independent 
predictor of death. This was observed in the PURSUIT 
study, where Latin American patients with unstable 
angina were twice as likely to die within 6 months as 
their North American counterparts, a difference not 
explained by the difference in baseline risk.15
One possible hypothesis explaining these contradic-
tory results may be the greater variability in the real-
world standard of care provided to patients with acute 
coronary syndromes, including the rate of revasculari-
zation, when compared to drug-eluting stent registries 
in which all patients were treated invasively. It should 
also be considered that most of the patients in SPIRIT 
Women had a stable clinical condition, representing 
a population less at risk. 
In both the Latin American and non-Latin Ameri-
can populations, we found a lower incidence of major 
adverse cardiac events when compared to the 15.7% 
reported by the NHLBI Dynamic Registry, in unselected 
women treated with drug-eluting stents, even when the 
lesions characteristics were similar. Also of note, stent 
thrombosis rates were 50% lower than in the female 
population of the this registry (1.3%).18
Two complications are of special interest for the 
female population because of their prevalence and 
prognostic impact. In-hospital bleeding was low and 
comparable in both regions. Vascular complications 
were significantly higher in hospitalized Latin American 
patients and even higher at 1 year, probably due to 
the fact that closure devices are not a standard of care. 
Limitations of the study
This study was limited by the single arm design and 
the inherent lack of a control arm for direct comparison. 
Lesion characteristics were assessed and reported by 
the investigator at the time of the procedure without 
the evaluation of a central laboratory.
TABLE 3 
Hierarchical adverse events at 1 year
 
Latin American
(n = 138)
Non-Latin American
(n = 1,434) P Value
Primary endpoint*, % 10.1 12.1 0.58
Target lesion failure†, % 9.4 10.7 0.77
Death, % 0.7 1.6 0.72
Myocardial infarction, % 9.4 8.9 0.88
Target vessel revascularization, % 0 0.4 > 0,99
* Death, myocardial infarction or target vessel revascularization.
† Cardiac death, myocardial infarction related to the target vessel or ischemia-guided target lesion revascularization.
n = number of patients.
Grinfeld et al.
SPIRIT Women Latin American Population
Rev Bras Cardiol Invasiva. 
2012;20(3)
7
All efforts were made to collect all adverse events; 
100% of source document was examined for reported 
adverse events and additional monitoring visits and 
source document verification were performed for sites 
with low rates of adverse events reporting. 
CONCLUSIONS
At 1 year, low rates of adverse cardiac events, 
including stent thrombosis, target vessel failure, car-
diac death, ARC defined MI and revascularization in 
the Latin-American cohort were comparable to those 
of the non-Latin American cohort despite the higher 
complexity of lesions. These results provide a strong 
demonstration of the safety and efficacy of XIENCE™ 
V in this small cohort of Latin American patients, in 
line with those of larger and more varied populations. 
This analysis highlights the need for further regional 
studies and reports.
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APPENDIX
Sponsor: Abbott Cardiovascular Systems, Inc., a subsidiary of Abbott Vascular (Santa Clara, CA, USA)
Principal investigator: Marie-Claude Morice (Paris, France)
Co-principal investigator: Stephan Windecker (Bern, Switzerland)
Steering Committee: Maria Grazia Modena (Italy), Ghada Mikhail (UK), Fina Mauri i Ferré (Spain), Ruth Strasser (Argentina), 
Liliana Grinfeld (Argentina)
Clinical Events Committee (CEC): K. Koch (Amsterdam, The Netherlands), B. Rensing (Utrecht, The Netherlands), G. 
Sianos (Thessaloniki, Greece), R. Tölgb (Bad Segeberg, Germany), M. Wiemer (Bad Oeynhausen, Germany), E. McFadden 
(Cork, Ireland), A. Hoye (Hull, UK)
Data Safety Monitoring Board (DSMB): J. Tijssen (Amsterdam, The Netherlands), T. Lefèvre (Massy, France), P. Urban 
(Geneva, Switzerland), K. Fox (Edingburgh, UK)
The following Latin American investigators and institutions participated in the SPIRIT Women Trial and number of 
patients enrolled: Alexandre Abizaid/Instituto Dante Pazzanese de Cardiologia (São Paulo, SP, Brazil) – 46 patients; 
Pedro Lemos/Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 
(São Paulo, SP, Brazil) – 24 patients; José M. Torres Viera/Clinica Santa Sofia (Caracas, Venezuela) – 20 patients; Liliana 
Grinfeld/Hospital Italiano de Buenos Aires (Buenos Aires, Argentina) – 19 patients; Jorge Belardi/Instituto Cardiovascular 
de Buenos Aires (Buenos Aires, Argentina) – 17 patients; Marcos Marino/Hospital Madre Teresa (Belo Horizonte, MG, 
Brazil) – 12 patients
